Comparison of the Effects of Topical Cyclosporine A 0.05%, Cyclosporine A 2%, Epinastine Hydrochloride 0.05%, and Prednisolone Acetate 1% on Allergic Inflammation in an Experimental Allergic Conjunctivitis Model

Basit Öğe Kaydı
dc.authoridBilak, Şemsettin/0000-0003-2552-4735
dc.authorwosidBilak, Şemsettin/AAF-2979-2019
dc.contributor.authorSemsettin, Bilak
dc.contributor.authorSinan, Emre
dc.contributor.authorNigar, Vardi
dc.date.accessioned2024-08-04T20:37:53Z
dc.date.available2024-08-04T20:37:53Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose:To investigate the effects of topical cyclosporine A 0.05%, cyclosporine A 2%, epinastine hydrochloride 0.05%, and prednisolone acetate 1% in an experimental allergic conjunctivitis model.Methods:Forty Wistar albino male rats were randomly divided into 5 groups. All the rats were immunized by an intraperitoneal injection of 100 g of ovalbumin. After 2 weeks, topical treatment was administered: cyclosporine A 0.05% 4 times a day to group 1, cyclosporine A 2% 4 times a day to group 2, epinastine HCl 0.05% 2 times a day to group 3, and prednisolone acetate 1% 4 times a day to group 4 for the following 7 days. Group 5 was designated as the control group. Both eyes of the rats were enucleated on the 22nd day of the study. The excised sections were stained by toluidine blue for mast cell count and by hematoxylin-eosin for histopathological evaluation.Results:The 2 solutions of cyclosporine A and epinastine were more effective than prednisolone acetate (P < 0.05) when compared with the control in histopathological scoring. There were statistically significant differences between the treatment groups and the control group (P < 0.05); however, no differences were observed between the treatment groups in the mast cell number.Conclusions:Topical 0.05% cyclosporine A is as effective as 2% cyclosporine A and epinastine in suppressing mast cell-mediated type I allergic conjunctivitis in an experimental allergic conjunctivitis model.en_US
dc.identifier.doi10.1097/ICO.0b013e3182a3655d
dc.identifier.endpage1469en_US
dc.identifier.issn0277-3740
dc.identifier.issn1536-4798
dc.identifier.issue11en_US
dc.identifier.pmid24055903en_US
dc.identifier.scopus2-s2.0-84886101231en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1465en_US
dc.identifier.urihttps://doi.org/10.1097/ICO.0b013e3182a3655d
dc.identifier.urihttps://hdl.handle.net/11616/96247
dc.identifier.volume32en_US
dc.identifier.wosWOS:000325921300014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofCorneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectallergic conjunctivitisen_US
dc.subjectcyclosporine Aen_US
dc.subjectepinastineen_US
dc.subjectprednisolone acetateen_US
dc.titleComparison of the Effects of Topical Cyclosporine A 0.05%, Cyclosporine A 2%, Epinastine Hydrochloride 0.05%, and Prednisolone Acetate 1% on Allergic Inflammation in an Experimental Allergic Conjunctivitis Modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu